Indications - Cosentyx PsA
Cosentyx (generic name: secukinumab) is a medication used to treat several autoimmune conditions. Here are the key indications for Cosentyx:
1. Plaque Psoriasis:
For adults with moderate to severe...
Did you mean: action?
- Twitter Linkedin Facebook Pinterest Google plus
Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 and for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusClinical efficacy & safety
The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...
Twitter Linkedin Facebook Pinterest Google plusIndication - Kesimpta
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features 1
Both newly diagnosed patients and patients switching from...
Twitter Linkedin Facebook Pinterest Google plusMechanism of Action (MoA)
Mechanism of Action (MoA)¹
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile - Jakavi
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...Twitter Linkedin Facebook Pinterest Google plusReimbursement
Mechanism of action - Cosentyx PsA
Cosentyx (secukinumab) is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A (IL-17A). 1 Cosentyx works by targeting IL-17A and inhibiting its interaction with...
Twitter Linkedin Facebook Pinterest Google plusNovartis – Notice d’information sur la protection des données à caractère personnel
Sept 2018 Cette Notice d'information vous est adressée car vous visitez un site internet d'une des sociétés du groupe Novartis. Par conséquent, nous procédons au traitement d'informations vous concernant, informations qui constituent des « données à...